Key result
Optimal cardiac delivery of modRNA was achieved using N1-Methylpseudouridine-5′-Triphosphate modification with specific dosing in vitro and 100 μg/mouse heart in sucrose-citrate buffer in vivo.
Population
Cardiac cells (cardiomyocytes) in vitro and mouse hearts in vivo
Design
Preclinical
Authors
Loading...
Optimizes modRNA cardiac delivery parameters in mice; leaves open translation to human therapies.
This study establishes optimized protocols for modified mRNA delivery to cardiac cells and tissue, enabling more effective gene transfer in cardiovascular disease models.
Sultana et al. (2017) studied Cardiovascular disease models. Modified mRNA (modRNA) delivery was evaluated on Optimal compositions of modRNA and reagents for cardiac expression. Optimal cardiac delivery of modRNA was achieved using N1-Methylpseudouridine-5′-Triphosphate modification with specific dosing in vitro and 100 μg/mouse heart in sucrose-citrate buffer in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: